Retsevmo (selpercatinib) vs Augtyro (repotrectinib)

Retsevmo (selpercatinib) and Augtyro (repotrectinib) are both targeted therapies designed to inhibit cancer growth in tumors with specific genetic alterations, such as those involving the RET proto-oncogene. Retsevmo is approved for the treatment of certain types of thyroid cancer and non-small cell lung cancer (NSCLC) with RET gene alterations, offering an option for patients with these specific mutations. Augtyro, still under clinical investigation as of the knowledge cutoff date, targets tumors with alterations in the ROS1 and NTRK genes, as well as RET, and may provide a broader range of application if approved, but its efficacy and safety profile will need to be compared with established treatments like Retsevmo upon completion of clinical trials. When deciding which medicine is right for an individual, it is crucial to consider the specific genetic makeup of the tumor, the safety and efficacy data of the medicines, and the approval status of the treatments by regulatory authorities.

Difference between Retsevmo and Augtyro

Metric	Retsevmo (selpercatinib)	Augtyro (repotrectinib)
Generic name	Selpercatinib	Repotrectinib
Indications	RET-driven lung cancers, thyroid cancers, and other solid tumors	Advanced solid tumors with NTRK or ROS1 gene fusions
Mechanism of action	RET kinase inhibitor	Tyrosine kinase inhibitor targeting TRK, ROS1, and ALK
Brand names	Retsevmo	Augtyro
Administrative route	Oral	Oral
Side effects	Increased liver enzymes, hypertension, dry mouth, diarrhea, fatigue, edema, rash	Fatigue, constipation, dizziness, edema, myalgia, cough, dyspnea
Contraindications	Hypersensitivity to selpercatinib	Hypersensitivity to repotrectinib
Drug class	Kinase inhibitor	Kinase inhibitor
Manufacturer	Eli Lilly and Company	Turning Point Therapeutics, Inc.

Efficacy

Efficacy of Retsevmo (selpercatinib) in Lung Cancer

Retsevmo (selpercatinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with RET (rearranged during transfection) gene alterations. The efficacy of Retsevmo was evaluated in a multicenter, open-label, multi-cohort clinical trial. The results demonstrated a significant response in patients with RET fusion-positive NSCLC who were previously treated with platinum chemotherapy. The objective response rate (ORR) was observed to be substantial, with many patients experiencing a reduction in tumor size. Additionally, the duration of response (DOR) indicated that the effects of Retsevmo were sustained over a period of time, providing a meaningful clinical benefit for patients with this specific genetic profile of lung cancer.

Furthermore, Retsevmo has also shown efficacy in RET fusion-positive NSCLC patients who are treatment-naive. In this population, the ORR was similarly high, suggesting that Retsevmo can be an effective first-line treatment option for patients with RET-altered lung cancer. The safety and efficacy of Retsevmo continue to be investigated in ongoing clinical trials, which aim to further define its role in the treatment landscape of lung cancer.

Efficacy of Augtyro (repotrectinib) in Lung Cancer

Augtyro (repotrectinib) is an investigational, next-generation tyrosine kinase inhibitor designed to target ROS1 and TRK A/B/C in NSCLC. While not yet approved for clinical use, early clinical trials have shown promising results in terms of its efficacy for treating ROS1-positive lung cancer. In phase I/II trials, repotrectinib has demonstrated a notable ORR in patients with ROS1-positive NSCLC, including those who have developed resistance to prior ROS1 inhibitors. This suggests that Augtyro could potentially serve as an effective treatment option for patients who have limited therapies available due to resistance mechanisms.

Repotrectinib's ability to overcome resistance is attributed to its potent and selective inhibition of ROS1, TRK, and ALK, which are common drivers of NSCLC. The drug's design allows it to maintain activity against a range of resistance mutations, which is a significant advancement in the treatment of lung cancer. The ongoing clinical development of Augtyro aims to further establish its efficacy and safety profile, with the goal of providing a new therapeutic option for patients with advanced NSCLC harboring specific genetic alterations.

Regulatory Agency Approvals

Retsevmo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Augtyro

Food and Drug Administration (FDA), USA

Access Retsevmo or Augtyro today

If Retsevmo or Augtyro are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Retsevmo

Buy Augtyro

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: